Drug intelligence / Profile preview

MSC_Apceth

Development stage: Phase 2
Lead developer: Apceth
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

MSC_Apceth is a cell therapy developed and GMP-manufactured by Apceth GmbH & Co. KG. It consists of autologous, ex-vivo expanded, non-hematopoietic mesenchymal stem cells derived from bone marrow. The drug is being investigated for the treatment of Critical Limb Ischemia.

Beyond the preview

Go deeper on MSC_Apceth.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC_Apceth.

Explore the full profile